We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gold-Based HDL-Nanoparticles Kill Lymphoma Cells without Drugs

By LabMedica International staff writers
Posted on 07 Feb 2013
Synthetic nanoparticles that mimic the look and behavior of HDLs (high-density lipoproteins) have been found to act as potent killers of human B-cell lymphoma cells both in cultures and in a mouse model without the necessity of associated anticancer drugs.

Investigators at Northwestern University (Chicago, IL, USA) synthesized HDL biomimetic nanoparticles capable of binding cholesterol. More...
These structures used a gold nanoparticle core as template for the assembly of a mixed phospholipid layer that adsorbed and intercalated molecules of apolipoprotein A-I. These synthesized structures had the general size and surface composition of natural HDL and, importantly, were able to bind free cholesterol.

Some cancer cells express receptors for HDLs due to their increased need for cholesterol. Accordingly, HDL-nanoparticles could be used as vehicles to deliver therapeutic agents to cancer cells expressing these HDL receptors. Moreover, a surprising study published in the January 23, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed that the HDL-nanoparticles by themselves were toxic to B-cell lymphoma cells without the necessity of associated anticancer drugs.

Like natural HDLs, the biomimetic HDL-nanoparticles targeted scavenger receptor type B-1, a high-affinity HDL receptor expressed by lymphoma cells. Use of the gold nanoparticle template enabled differential manipulation of cellular cholesterol flux, promoting transport of cholesterol away from the cells while limiting cholesterol delivery to the cells. This combination of scavenger receptor type B-1 binding and relative cholesterol starvation selectively induced apoptosis and ultimately death of the cancer cells.

In mice bearing B-cell lymphoma xenografts, treatment with HDL-nanoparticles selectively inhibited tumor growth.

"This has the potential to eventually become a nontoxic treatment for B-cell lymphoma, which does not involve chemotherapy," said contributing author Dr. Leo I. Gordon, professor of hematology and oncology at Northwestern University. "It is an exciting preliminary finding."

The investigators reported being particularly encouraged by early data showing that the HDL nanoparticles did not appear to be toxic to other human cells normally targeted by HDLs, normal human lymphocytes, or to mice.

Related Links:
Northwestern University




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.